Division of GlaxoSmithKline PLC
Latest From ViiV Healthcare
Biktarvy’s powerful sales growth and the potential of a first-in-class capsid inhibitor in both prevention and heavily treatment-experienced patients are key to Gilead’s plan for staying on top in HIV.
The view from 2020: Scrip looks back at the most successful commercial launches of the decade.
The latest news on novel drug approvals and complete response letters from our US FDA Performance Tracker.
CDER's 48 novel agents, including 35 in the second half of the year, marks the second-highest novel approval count in the contemporary era.
- Therapeutic Areas
- Infectious & Viral Diseases
- GSK Pfizer HIV
- Western Europe
- Parent & Subsidiaries
- GlaxoSmithKline PLC
- Senior Management
Jerome Andries, CFO
John Pottage, MD, CSO & CMO
Gregory Reinaud, Head, Global Commercial Strategy
- Contact Info
Phone: (44) (0)20 8380 6200
980 Great West Rd.
Brentford, TW8 9GS
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.